An international team of scientists from the Paul Scherrer Institute and members of the LeadXpro and Heptares pharmaceutical companies led by Karol Nass (Alvra group, SwissFEL) demonstrated a significant advancement in de novo protein structure determination at X-ray free-electron lasers. Their article, published recently in IUCrJ (DOI: 10.1107/S2052252520011379), describes structure determination of a membrane protein and an important drug target (A2A adenosine receptor) by native single-wavelength anomalous diffraction (native-SAD) at SwissFEL with up to ten fold reduction in the required number of indexed images.